Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

NCT02955940 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02955940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02955940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 30, 2016
Completion date
September 30, 2027
Enrollment
10 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer (crc), lung cancer, pancreatic cancer